Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2010 Apr 1;201(7):981-3.
doi: 10.1086/651143.

HIV neutralizing antibodies: clinical correlates and implications for vaccines

Nicole A Doria-Rose
Editorial

HIV neutralizing antibodies: clinical correlates and implications for vaccines

Nicole A Doria-Rose. J Infect Dis. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The author declares no conflict of interests.

Comment on

References

    1. Gray ES, Moore PL, Choge IA, et al. Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J Virol. 2007;81:6187–6196. - PMC - PubMed
    1. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A. 2003;100:4144–4149. - PMC - PubMed
    1. Beirnaert E, Nyambi P, Willems B, et al. Identification and characterization of sera from HIV-infected individuals with broad cross-neutralizing activity against group M (env clade A-H) and group O primary HIV-1 isolates. J Med Virol. 2000;62:14–24. - PubMed
    1. Moore JP, Cao Y, Leu J, Qin L, Korber B, Ho DD. Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J Virol. 1996;70:427–444. - PMC - PubMed
    1. Graham BS. Clinical trials of HIV vaccines. Annu Rev Med. 2002;53:207–221. - PubMed

MeSH terms